A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

NCT05229068 · clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in this study.

Conditions

Interventions

Sponsor

GlaxoSmithKline